Cargando…

Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients

Detalles Bibliográficos
Autor principal:	Farag, Youssef M.K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mayo Foundation for Medical Education and Research 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528833/ https://www.ncbi.nlm.nih.gov/pubmed/33276848 http://dx.doi.org/10.1016/j.mayocp.2020.09.033

Ejemplares similares

In Reply — Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Joyner, Michael. J., et al.
Publicado: (2020)

COVID-19convalescent plasma use in the oncology and geriatric patients: Ethical aspects in transfusion medicine
por: Bansal, N., et al.
Publicado: (2022)

Use of convalescent plasma in COVID-19 patients in China
por: Zhu, M., et al.
Publicado: (2020)

Convalescent plasma for COVID-19 considerations
por: Adiwinata Pawitan, Jeanne
Publicado: (2021)

COVID-19 convalescent plasma transfusion
por: Langhi, Dante Mário, et al.
Publicado: (2020)

Possible Transfusion-Related Acute Lung Injury Following Convalescent Plasma Transfusion in a Patient With Middle East Respiratory Syndrome
por: Chun, Sejong, et al.
Publicado: (2016)

Convalescent plasma (CP) therapy in patients with COVID-19
por: Cakir, Banu
Publicado: (2021)

Convalescent plasma in the management of COVID-19 pneumonia
por: Elbadawi, Ayman, et al.
Publicado: (2021)

How Safe Is COVID-19 Convalescent Plasma?
por: Franchini, Massimo, et al.
Publicado: (2021)

COVID-19 convalescent plasma therapy and immunodeficiency
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Convalescent plasma transfusion for pregnant patients with COVID-19
por: Mastroianni, Antonio, et al.
Publicado: (2021)

‘Treatment of COVID-19 with convalescent plasma’ – Author’s reply
por: Wooding, Denise J., et al.
Publicado: (2021)

In Reply—How Safe Is COVID-19 Convalescent Plasma?
por: Joyner, Michael J., et al.
Publicado: (2021)

Elevated Rate of HLA Antibodies in Male COVID-19 Convalescent Plasma Donors: A Risk Factor for Transfusion-Related Acute Lung Injury
por: Juskewitch, Justin E., et al.
Publicado: (2021)

Treatment of COVID-19: Perspective on Convalescent Plasma Transfusion
por: Farhat, Ryan M., et al.
Publicado: (2020)

Convalescent plasma for patients with COVID-19
por: Zeng, Furong, et al.
Publicado: (2020)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Plasma exchange followed by convalescent plasma transfusion in COVID-19 patients
por: Roshandel, Elham, et al.
Publicado: (2021)

Early and persistent viral clearance in COVID-19 patients treated with convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2021)

Convalescent plasma to treat COVID-19: Its challenges in Iraq's situation
por: Hashim, H.T.
Publicado: (2020)

Challenges in the production of COVID-19 convalescent plasma- analysis of donor recruitment
por: Sekiya, Eliseo Joji, et al.
Publicado: (2021)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response)
por: De Santis, Gil C., et al.
Publicado: (2022)

COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors
por: Bansal, N., et al.
Publicado: (2021)

The emergency use authorization for COVID‐19 convalescent plasma reduced mortality
por: Paneth, Nigel, et al.
Publicado: (2023)

Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy
por: London, Jonathan, et al.
Publicado: (2020)

COVID-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits
por: Vuk, T., et al.
Publicado: (2021)

Convalescent plasma transfusion a promising therapy for coronavirus diseases 2019 (COVID-19): current updates
por: Verma, Henu Kumar, et al.
Publicado: (2020)

Antimicrobial stewardship programs and convalescent plasma for COVID-19: A new paradigm for preauthorization?
por: Stevens, Michael P., et al.
Publicado: (2020)

Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion
por: Xia, Xinyi, et al.
Publicado: (2020)

Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma
por: Vazquez, Sara E., et al.
Publicado: (2021)

Covid-19 convalescent plasma and SARS-CoV-2 viral variants
por: Joob, B., et al.
Publicado: (2021)

Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients
por: Joyner, Michael J., et al.
Publicado: (2020)

Transfusion reaction to hyperimmune plasma in patients with severe COVID-19 infection()
por: Edroso Jarne, Paloma Eugenia, et al.
Publicado: (2021)

Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19
por: Rodionov, Roman N, et al.
Publicado: (2021)

Impact of convalescent and nonimmune plasma on mortality of patients with COVID-19: a potential role for antithrombin
por: Gazzaruso, Carmine, et al.
Publicado: (2021)

A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma
por: Iaboni, Aled, et al.
Publicado: (2021)

Resolution of Persistent COVID-19 After Convalescent Plasma in a Patient with B Cell Aplasia
por: McKemey, Emily, et al.
Publicado: (2021)

Convalescent plasma: A possible treatment of COVID-19 in India
por: Teixeira da Silva, Jaime A.
Publicado: (2020)

Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?
por: Basic-Jukic, Nikolina
Publicado: (2020)

Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b888tp46spuvfs55u5bjrkv0v2